Roche presents five-year survival outcomes for Tecentriq plus chemotherapy in ES-SCLC EP News Bureau Sep 11, 2023 IMbrella A, an extension of the Phase III IMpower133 study, demonstrates the potential for a durable overall survival benefit with…
